A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

China: CAR T-cell therapy, already in use for certain B-cell–driven autoimmune diseases such as lupus, has now demonstrated ...

The ongoing phase I/II clinical trial is evaluating the safety, tolerability and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001 Preliminary findings include a ...

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, will present new ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

Please provide your email address to receive an email when new articles are posted on . Although chimeric antigen receptor T-cell therapy has delivered previously unthinkable remission outcomes to ...